CareDx (CDNA) Receives News Impact Rating of 0.11
Media stories about CareDx (NASDAQ:CDNA) have been trending somewhat positive on Wednesday, Accern reports. Accern identifies negative and positive press coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. CareDx earned a daily sentiment score of 0.11 on Accern’s scale. Accern also assigned media stories about the company an impact score of 46.2846351738258 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.
Here are some of the media stories that may have effected Accern Sentiment’s rankings:
- CareDx Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (finance.yahoo.com)
- AlloSure data will be presented at ASN (feeds.benzinga.com)
- CareDx, Inc. (CDNA) Short Interest Update (americanbankingnews.com)
- CareDx to Announce Third Quarter 2017 Financial Results on November 9, 2017 (finance.yahoo.com)
CareDx (NASDAQ CDNA) opened at 5.85 on Wednesday. The stock has a 50 day moving average price of $4.62 and a 200 day moving average price of $2.23. CareDx has a 52-week low of $0.76 and a 52-week high of $6.69. The firm’s market cap is $131.86 million.
CareDx (NASDAQ:CDNA) last posted its quarterly earnings results on Thursday, August 10th. The company reported ($0.19) EPS for the quarter, hitting analysts’ consensus estimates of ($0.19). The company had revenue of $12.05 million for the quarter, compared to analysts’ expectations of $11.87 million. CareDx had a negative net margin of 61.27% and a negative return on equity of 85.68%. Equities analysts predict that CareDx will post ($0.82) earnings per share for the current fiscal year.
A number of brokerages have weighed in on CDNA. Craig Hallum reissued a “buy” rating and set a $10.00 price target (up previously from $4.00) on shares of CareDx in a research report on Monday, October 9th. Raymond James Financial, Inc. raised CareDx from a “market perform” rating to a “buy” rating and set a $6.50 price target on the stock in a research report on Wednesday, September 27th. ValuEngine raised CareDx from a “strong sell” rating to a “sell” rating in a research report on Tuesday, September 26th. Piper Jaffray Companies reissued an “overweight” rating and set a $7.00 price target (up previously from $3.00) on shares of CareDx in a research report on Tuesday, September 26th. Finally, Zacks Investment Research downgraded CareDx from a “buy” rating to a “hold” rating in a research report on Monday, September 11th. One equities research analyst has rated the stock with a sell rating and four have assigned a buy rating to the company. CareDx presently has an average rating of “Buy” and an average price target of $6.69.
TRADEMARK VIOLATION WARNING: This piece of content was first published by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are reading this piece of content on another site, it was stolen and reposted in violation of US & international trademark & copyright legislation. The legal version of this piece of content can be viewed at https://theolympiareport.com/2017/11/01/caredx-cdna-receives-news-impact-rating-of-0-11.html.
In related news, major shareholder Neil Gagnon purchased 21,448 shares of the stock in a transaction that occurred on Monday, August 28th. The shares were bought at an average price of $2.77 per share, with a total value of $59,410.96. Following the acquisition, the insider now owns 903,731 shares of the company’s stock, valued at approximately $2,503,334.87. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Insiders purchased a total of 75,030 shares of company stock worth $226,758 in the last ninety days. 5.40% of the stock is currently owned by insiders.
CareDx, Inc is a molecular diagnostics company. The Company is focused on the discovery, development and commercialization of clinically differentiated diagnostic surveillance solutions for transplant patients. The Company’s commercialized testing solution, the AlloMap heart transplant molecular test (AlloMap), is a gene expression test that helps clinicians monitor and identify heart transplant recipients with stable graft function having a low probability of moderate/severe acute cellular rejection.
Receive News & Ratings for CareDx Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CareDx Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.